Lazertinib + Platinum-based Chemotherapy
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Trial Timeline
Jun 1, 2015 → Mar 20, 2023
NCT ID
NCT05862194About Lazertinib + Platinum-based Chemotherapy
Lazertinib + Platinum-based Chemotherapy is a pre-clinical stage product being developed by Yuhan for Non-small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05862194. Target conditions include Non-small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05862194 | Pre-clinical | Completed |
Competing Products
20 competing products in Non-small Cell Lung Cancer